Paying users zone. Data is hidden behind .
Get 1-month access to Bristol-Myers Squibb Co. for $17.99, or
get full access to the entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Bristol-Myers Squibb Co. (BMY)
Analysis of Profitability Ratios
Beginner level
Profitability ratios measure the company’s ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Bristol-Myers Squibb Co., profitability ratios
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
Profitability ratio | Description | The company |
---|---|---|
Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Bristol-Myers Squibb Co.’s gross profit margin ratio deteriorated from 2016 to 2017 but then slightly improved from 2017 to 2018. |
Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Bristol-Myers Squibb Co.’s operating profit margin ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 not reaching 2016 level. |
Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Bristol-Myers Squibb Co.’s net profit margin ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 not reaching 2016 level. |
Profitability ratio | Description | The company |
---|---|---|
ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Bristol-Myers Squibb Co.’s ROE deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level. |
ROA | A profitability ratio calculated as net income divided by total assets. | Bristol-Myers Squibb Co.’s ROA deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level. |
Gross Profit Margin
Bristol-Myers Squibb Co., gross profit margin calculation, comparison to benchmarks
Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Gross margin | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Revenues | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Profitability Ratio | ||||||
Gross profit margin1 | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Benchmarks | ||||||
Gross Profit Margin, Competitors2 | ||||||
Abbott Laboratories | ![]() |
![]() |
![]() |
![]() |
![]() |
|
AbbVie Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Allergan PLC | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Amgen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Biogen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Eli Lilly & Co. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Gilead Sciences Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Johnson & Johnson | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Merck & Co. Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Pfizer Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Regeneron Pharmaceuticals Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
1 2018 Calculation
Gross profit margin = 100 × Gross margin ÷ Revenues
= 100 × ÷
=
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Bristol-Myers Squibb Co.’s gross profit margin ratio deteriorated from 2016 to 2017 but then slightly improved from 2017 to 2018. |
Operating Profit Margin
Bristol-Myers Squibb Co., operating profit margin calculation, comparison to benchmarks
Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Operating income | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Revenues | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Profitability Ratio | ||||||
Operating profit margin1 | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Benchmarks | ||||||
Operating Profit Margin, Competitors2 | ||||||
Abbott Laboratories | ![]() |
![]() |
![]() |
![]() |
![]() |
|
AbbVie Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Allergan PLC | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Amgen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Biogen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Eli Lilly & Co. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Gilead Sciences Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Johnson & Johnson | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Merck & Co. Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Pfizer Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Regeneron Pharmaceuticals Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Operating Profit Margin, Sector | ||||||
Pharmaceuticals & Biotechnology | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Operating Profit Margin, Industry | ||||||
Health Care | ![]() |
![]() |
![]() |
![]() |
![]() |
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
1 2018 Calculation
Operating profit margin = 100 × Operating income ÷ Revenues
= 100 × ÷
=
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Bristol-Myers Squibb Co.’s operating profit margin ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 not reaching 2016 level. |
Net Profit Margin
Bristol-Myers Squibb Co., net profit margin calculation, comparison to benchmarks
Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net earnings attributable to BMS | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Revenues | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Profitability Ratio | ||||||
Net profit margin1 | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Benchmarks | ||||||
Net Profit Margin, Competitors2 | ||||||
Abbott Laboratories | ![]() |
![]() |
![]() |
![]() |
![]() |
|
AbbVie Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Allergan PLC | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Amgen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Biogen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Eli Lilly & Co. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Gilead Sciences Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Johnson & Johnson | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Merck & Co. Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Pfizer Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Regeneron Pharmaceuticals Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Net Profit Margin, Sector | ||||||
Pharmaceuticals & Biotechnology | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Net Profit Margin, Industry | ||||||
Health Care | ![]() |
![]() |
![]() |
![]() |
![]() |
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
1 2018 Calculation
Net profit margin = 100 × Net earnings attributable to BMS ÷ Revenues
= 100 × ÷
=
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Bristol-Myers Squibb Co.’s net profit margin ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 not reaching 2016 level. |
Return on Equity (ROE)
Bristol-Myers Squibb Co., ROE calculation, comparison to benchmarks
Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net earnings attributable to BMS | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Total Bristol-Myers Squibb Company shareholders’ equity | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Profitability Ratio | ||||||
ROE1 | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Benchmarks | ||||||
ROE, Competitors2 | ||||||
Abbott Laboratories | ![]() |
![]() |
![]() |
![]() |
![]() |
|
AbbVie Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Allergan PLC | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Amgen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Biogen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Eli Lilly & Co. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Gilead Sciences Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Johnson & Johnson | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Merck & Co. Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Pfizer Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Regeneron Pharmaceuticals Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
ROE, Sector | ||||||
Pharmaceuticals & Biotechnology | ![]() |
![]() |
![]() |
![]() |
![]() |
|
ROE, Industry | ||||||
Health Care | ![]() |
![]() |
![]() |
![]() |
![]() |
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
1 2018 Calculation
ROE = 100 × Net earnings attributable to BMS ÷ Total Bristol-Myers Squibb Company shareholders’ equity
= 100 × ÷
=
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Bristol-Myers Squibb Co.’s ROE deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level. |
Return on Assets (ROA)
Bristol-Myers Squibb Co., ROA calculation, comparison to benchmarks
Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Net earnings attributable to BMS | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Total assets | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Profitability Ratio | ||||||
ROA1 | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Benchmarks | ||||||
ROA, Competitors2 | ||||||
Abbott Laboratories | ![]() |
![]() |
![]() |
![]() |
![]() |
|
AbbVie Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Allergan PLC | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Amgen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Biogen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Eli Lilly & Co. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Gilead Sciences Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Johnson & Johnson | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Merck & Co. Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Pfizer Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Regeneron Pharmaceuticals Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
ROA, Sector | ||||||
Pharmaceuticals & Biotechnology | ![]() |
![]() |
![]() |
![]() |
![]() |
|
ROA, Industry | ||||||
Health Care | ![]() |
![]() |
![]() |
![]() |
![]() |
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
1 2018 Calculation
ROA = 100 × Net earnings attributable to BMS ÷ Total assets
= 100 × ÷
=
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
ROA | A profitability ratio calculated as net income divided by total assets. | Bristol-Myers Squibb Co.’s ROA deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level. |